Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma.
Chiara MonfriniFederico StellaVanessa AragonaMartina MagniSilva LjevarCristina VellaEugenio FardellaAnnalisa ChiappellaFrancesca NanettiMartina PennisiAnna DoderoAnna GuidettiPaolo CorradiniCristiana CarnitiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Our data indicate that despite the great heterogeneity of Tisa-cel and Axi-cel products, the differentiation status of the infused cells mediates CAR T-cell in vivo proliferation that is necessary for antitumor response.